Itron (NASDAQ:ITRI) Downgraded by Wall Street Zen to Hold

Itron (NASDAQ:ITRI) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Monday.

Several other research firms have also recently commented on ITRI. Robert W. Baird restated a “neutral” rating and issued a $118.00 target price (down from $137.00) on shares of Itron in a research report on Friday, October 31st. Stephens raised Itron from an “equal weight” rating to an “overweight” rating and set a $130.00 price target for the company in a research note on Monday, November 3rd. Zacks Research cut shares of Itron from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Oppenheimer set a $145.00 price objective on shares of Itron and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Baird R W lowered shares of Itron from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Nine research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Itron has a consensus rating of “Moderate Buy” and an average price target of $139.00.

Itron Trading Up 0.6%

Itron stock opened at $96.46 on Monday. Itron has a 52-week low of $90.11 and a 52-week high of $142.00. The company has a quick ratio of 1.91, a current ratio of 2.17 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $4.42 billion, a price-to-earnings ratio of 17.35, a PEG ratio of 0.47 and a beta of 1.52. The firm has a 50-day moving average price of $104.52 and a two-hundred day moving average price of $119.33.

Itron (NASDAQ:ITRI) last announced its quarterly earnings results on Thursday, October 30th. The scientific and technical instruments company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.48 by $0.06. The company had revenue of $581.63 million for the quarter, compared to analyst estimates of $578.49 million. Itron had a net margin of 10.69% and a return on equity of 17.82%. Itron’s revenue was down 5.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.84 earnings per share. Itron has set its FY 2025 guidance at 6.840-6.940 EPS and its Q4 2025 guidance at 2.150-2.250 EPS. Sell-side analysts expect that Itron will post 5.33 earnings per share for the current year.

Insiders Place Their Bets

In other Itron news, SVP Christopher E. Ware sold 343 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $96.51, for a total value of $33,102.93. Following the sale, the senior vice president directly owned 18,774 shares in the company, valued at approximately $1,811,878.74. The trade was a 1.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Joan S. Hooper sold 948 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $96.51, for a total transaction of $91,491.48. Following the completion of the sale, the chief financial officer directly owned 87,446 shares of the company’s stock, valued at $8,439,413.46. The trade was a 1.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 2,971 shares of company stock valued at $286,731. 1.51% of the stock is currently owned by insiders.

Institutional Trading of Itron

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Impax Asset Management Group plc lifted its stake in Itron by 127.3% during the third quarter. Impax Asset Management Group plc now owns 1,588,950 shares of the scientific and technical instruments company’s stock valued at $197,153,000 after purchasing an additional 890,040 shares during the last quarter. Norges Bank acquired a new position in Itron in the second quarter worth approximately $71,727,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Itron by 129.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 732,274 shares of the scientific and technical instruments company’s stock valued at $76,713,000 after buying an additional 413,487 shares in the last quarter. Merewether Investment Management LP lifted its position in shares of Itron by 1,552.7% during the 2nd quarter. Merewether Investment Management LP now owns 300,787 shares of the scientific and technical instruments company’s stock valued at $39,593,000 after acquiring an additional 282,587 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Itron by 42.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 604,580 shares of the scientific and technical instruments company’s stock valued at $75,306,000 after acquiring an additional 180,366 shares during the last quarter. 96.19% of the stock is currently owned by institutional investors.

Itron Company Profile

Itron, Inc (NASDAQ: ITRI) is a global technology company that develops innovative solutions to measure, manage and analyze the use of energy and water. Its comprehensive portfolio includes smart meters, data collection devices, communication networks and advanced software applications designed to optimize utility operations and foster sustainable resource management. The company’s offerings enable utilities and cities to accurately monitor consumption patterns, streamline billing processes and improve grid reliability.

Itron’s product lineup spans a range of hardware and software solutions, from residential and commercial smart meters to meter data management systems (MDMS), networked communication platforms and analytics tools.